Johan Mellergård

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

Johan Mellergård, Måns Edström, Magnus Vrethem et al. · Multiple Sclerosis Journal · 2009 · 151 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Anders Svenningsson, Thomas Frisell, Joachim Burman et al. · The Lancet Neurology · 2022 · 124 citations

Medicine, Internal Medicine, Neurology +9

Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

Julia Åkesson, Sara Hojjati, Sandra Hellberg et al. · Nature Communications · 2023 · 94 citations · Full text

Life Sciences, Neurology, Neuroscience +17

A validated gene regulatory network and GWAS identifies early regulators of T cell–associated diseases

Mika Gustafsson, Danuta R. Gawel, Lars Alfredsson et al. · Science Translational Medicine · 2015 · 82 citations · Full text

Life Sciences, Genetics, Immunology +17

Increased B Cell and Cytotoxic NK Cell Proportions and Increased T Cell Responsiveness in Blood of Natalizumab-Treated Multiple Sclerosis Patients

Johan Mellergård, Måns Edström, Maria C. Jenmalm et al. · PLoS ONE · 2013 · 42 citations · Full text

Life Sciences, Cell Biology, Immunology +17